ClinicalTrials.gg

Program

gallium 68 PSMA-11

Also written as “68Ga-PSMA-11”, “AAA517” and “Gallium (68Ga) gozetotide”.

Its studies are mostly in Prostatic Neoplasms, led by 2 companies.

Furthest: phase 3, since Apr 27, 20234 company-led studies, 3 open or runningNext primary completion: Dec 23, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis21 open or runningphase 2since Apr 27, 2023Apr 27, 2023Dec 23, 2026phase 2 · NCT05849298
Telix Pharmaceuticals22 open or runningphase 3since Apr 5, 2023Apr 5, 2023Jan 2027phase 3 · NCT07052214

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 5, 2023First study: phase 3 study in Prostatic NeoplasmsNew to Telix PharmaceuticalsTelix Pharmaceuticals · NCT05847348 · 110 planned · China
  2. Apr 27, 2023Novartis’s first study: phase 2 study in Prostatic NeoplasmsNew to NovartisNovartis · NCT05849298 · 49 enrolled · United States, Brazil, Canada and more
  3. Feb 25, 2025Phase 2 study in Prostatic NeoplasmsNovartis · NCT06881823
  4. Jun 26, 2025Phase 3 study in Prostatic NeoplasmsTelix Pharmaceuticals · NCT07052214 · 338 enrolled · United States, Australia

Ahead

  1. Dec 23, 2026Primary completion: phase 2 study in Prostatic NeoplasmsNovartis · NCT05849298
  2. Jan 2027Primary completion: phase 3 study in Prostatic NeoplasmsTelix Pharmaceuticals · NCT07052214

TargetBeta

FOLH1 →read by rule
“A radioconjugate composed of a human prostate specific membrane antigen (PSMA)-targeting ligand, Glu-urea-Lys(Ahx) (Glu-NH-CO-NH-Lys(Ahx)), ”NCIt, by rule

Other programs on FOLH1

ProgramCompanyFurthest phaseStudies
flotufolastat F 18ruleBraccophase 47
piflufolastatruleLantheusphase 45
abefolastat tesaroxetan CU-64ruleclarity-pharmaceuticals-ltdphase 35
Lutetium Lu 177 Ludotadipeprulefuturechemphase 33
Anti-PSMA/Anti-CD28 Bispecific Antibody JNJ-87189401Johnson & Johnsonphase 32
Lutetium Lu 177 NYM032ruleNorroy Biosciencephase 32
actinium AC-225 vipivotide tetraxetanNovartisphase 32
HRS-4357Jiangsu HengRui Medicinephase 32
zadavotide guraxetanAstraZenecaphase 24
AB-001rulefrontier-biotechnologies-incphase 23
olsutamigruleRegeneron Pharmaceuticalsphase 22
SHR-4394Jiangsu HengRui Medicinephase 22

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07052214Prostatic Neoplasms · United States, Australia3Active, not recruitingTelix PharmaceuticalsJan 2027338
NCT06881823Prostatic Neoplasms2WithdrawnNovartisMar 31, 20300
NCT05849298Prostatic Neoplasms · United States, Brazil, Canada and more2Active, not recruitingNovartisDec 23, 202649
NCT05847348Prostatic Neoplasms · China3RecruitingTelix PharmaceuticalsDec 30, 2025110

How it is read

Names in the registry

  • “68Ga-PSMA-11”, 2 entries
  • “AAA517”, 1 entry
  • “Gallium (68Ga) gozetotide”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.